Biora Therapeutics, Inc. BIORQ
- Market cap
- $2.5M
- P/E
- 0.0×
Follow BIORQ
Target Price Range
Analyst price targets
Free account| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 770.00 | 164.25 | 32.75 | 10.50 |
Analyst estimates 2024–2026 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | 3,980.00 | 1,965.00 | 577.50 | 76.80 |
High Price
|
|||
| — | — | — | — | — | 674 | 649 | 124 | 54 | 58 |
Employees
|
|||
| — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | 128 | 144 | 0 | 1 | 0 | 0 |
Revenue
|
|||
| — | — | — | — | 28.05% | 30.21% | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
|
|||
| — | — | — | — | (124) | (149) | (143) | (179) | (49) | (124) |
EBT
|
|||
| — | — | — | — | (96.78%) | (103.30%) | (88,035.80%) | (14,325.58%) | (16,147.54%) | (3,110,600.00%) |
EBT Margin
|
|||
| — | — | — | 0 | (129) | (148) | (193) | (247) | (38) | (124) |
Net Income
|
|||
| — | — | — | — | 6 | 6 | 5 | 3 | 2 | 2 |
Depreciation
|
|||
| — | — | — | — | 69.30 | 7,383.85 | 1.47 | 3.24 | 0.40 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | (69.92) | (7,579.20) | (1,752.50) | (642.50) | (50.00) | (78.70) |
Earnings/Sh
|
|||
| — | — | — | — | (35.27) | (5,442.26) | (1,505.40) | (435.48) | (84.37) | (30.75) |
Cash Flow/Sh
|
|||
| — | — | — | — | 0.00 | (191.03) | (35.16) | (2.22) | (1.04) | (0.06) |
Capex/Sh
|
|||
| — | — | — | — | (35.27) | (5,633.28) | (1,540.55) | (437.70) | (85.41) | (30.81) |
Free CF/Sh
|
|||
| — | — | — | — | (20.02) | (4,301.23) | (971.79) | (220.95) | (133.97) | (64.30) |
Book Value/Sh
|
|||
| — | — | — | — | 2 | 0 | 0 | 0 | 1 | 2 |
Shares
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | 0.58 | 0.58 | 7.64 | 278.35 | 58.83 | 214.06 |
PS Ratio
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | 1.12 | 1.12 | 9.63 | 308.82 | 380.85 | 525.30 |
EV/Sales
|
|||
| — | — | — | — | (0.89) | (0.89) | (1.95) | (2.29) | (1.78) | (1.06) |
EV/FCF
|
|||
| — | — | — | — | (65) | (106) | (166) | (167) | (64) | (48) |
Op' Cash Flow
|
|||
| — | — | — | — | (5) | (4) | (4) | (1) | (1) | 0 |
Capex
|
|||
| — | — | — | — | (65) | (110) | (170) | (168) | (65) | (49) |
FCF
|
|||
| — | — | — | — | 11 | (26) | 54 | 37 | 15 | (44) |
Working Cap'
|
|||
| — | — | — | — | 73 | 4 | 160 | 126 | 129 | 46 |
Total Debt
|
|||
| — | — | — | — | 4 | (29) | 68 | 38 | 98 | 31 |
Net Debt
|
|||
| — | — | — | — | (37) | (84) | (107) | (85) | (102) | (101) |
Sh' Equity
|
|||
| — | — | — | — | (221.84%) | (209.81%) | (150.52%) | (187.95%) | (47.00%) | (292.93%) |
ROA
|
|||
| — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | 213.45% | 378.33% | 201.91% | 257.76% | 40.75% | 121.86% |
ROE
|
|||
Biora Therapeutics, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| EIGRQ Eiger BioPharmaceuticals, Inc. | $2.6M | 0.0× | Compare |
| CDT CDT Equity Inc. | $2.4M | 0.0× | Compare |
| MTNB Matinas Biopharma Holdings, Inc. | $2.4M | 0.0× | Compare |
| PPBT Purple Biotech Ltd. Sponsored ADR | $2.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NTBLQ Notable Labs, Ltd. | $2.4M | 0.0× | Compare |
| BPTSY Biophytis SA Sponsored ADR | $2.4M | 0.0× | Compare |
| WINT Windtree Therapeutics, Inc. | $2.4M | 0.0× | Compare |
| ARTL Artelo Biosciences, Inc. | $2.7M | 0.0× | Compare |
Biora Therapeutics, Inc. (BIORQ) key facts
- Biora Therapeutics, Inc. (BIORQ) is a Biotechnology company in the Healthcare sector.
- Biora Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $4,000.00, down 98.7% from fiscal 2022.
- Return on equity was 121.9% and debt-to-equity -0.18.
Biora Therapeutics, Inc. (BIORQ) Latest News
31 Mar
Biora Therapeutics, Inc. has successfully completed its restructuring process, which is expected to enhance operational efficiency and streamline its focus on core therapeutic areas. The company aims to strengthen its financial position and improve its product development pipeline following this strategic move. The restructuring process is likely to significantly impact the company's operational efficiency and focus, potentially altering its trajectory and investor sentiment.
31 Dec
Biora Therapeutics, Inc. is undergoing a Chapter 11 sales process. Chapter 11 sales process could significantly alter the company's trajectory and investor sentiment.
30 Dec
Biora Therapeutics filed for Chapter 11 and secured $10.25 million financing for sale process. Chapter 11 filing and financing for sale process are significant events that could alter the company's trajectory.
Biora Therapeutics, Inc. undertakes chapter 11 sale process to strengthen balance sheet and support product development with up to $10.25 million in financing. The chapter 11 sale process and financing are expected to have a significant impact on Biora Therapeutics, Inc.'s future trajectory and market performance.
14 Nov
Biora Therapeutics reported financial results for Q3 2024, highlighted progress on BioJet device development, NaviCap platform, and funding activities. The article discusses significant advancements in key platforms and funding, which could have a major impact on the company's future trajectory.
7 Nov
Biora Therapeutics, Inc. (BIOR) will report third quarter 2024 financial results and provide a corporate update. The financial results and corporate update may moderately influence key areas such as financial performance and competitive positioning.
29 Oct
Biora Therapeutics announces $3 million registered direct offering priced at-the-market under Nasdaq rules. The offering and concurrent private placement are expected to have a significant impact on Biora Therapeutics' future operations and financial position.
28 Oct
Biora Therapeutics shares progress on smaller BioJet™ clinical device with largest payload of any ingestible injectable at the 14th Annual PODD Meeting. Development of BioJet™ platform with potential to replace injections and achieve high oral bioavailability for large molecules.
14 Oct
Biora Therapeutics to reveal 00-size BioJet™ device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting. Announcement of new 00-size BioJet™ device with increased payload capacity expected to significantly impact future product innovation and competitive positioning.
7 Oct
Biora Therapeutics to present at the 19th Annual Peptide Therapeutics Symposium on empowering peptide self-administration with needle-free smart capsules. Presentation at a prestigious symposium showcasing innovative technology with potential to significantly impact the company's future and market performance.
30 Sep
Biora Therapeutics will present an award-winning abstract at the ACG Annual Scientific Meeting in October 2024. The award-winning abstract presentation at a prestigious scientific meeting is likely to have a significant impact on Biora Therapeutics' future and market performance.
9 Sep
Biora Therapeutics, Inc. achieves ISO 13485 certification, demonstrating commitment to quality and compliance with global regulatory standards. ISO 13485 certification is a significant achievement that can impact Biora Therapeutics' future regulatory approvals and market credibility.
28 Aug
Biora Therapeutics granted extension to regain compliance with Nasdaq listing requirements, subject to meeting market value and bid price rules by November 7, 2024. The extension granted by Nasdaq could moderately influence Biora Therapeutics' future financial performance and competitive positioning.
26 Aug
Biora Therapeutics will present at H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024. Participation in the conference may moderately influence investor sentiment and future developments.
15 Aug
Biora Therapeutics, Inc. reported second quarter results, including financial data, progress with BT-600 trial, BioJet partnership discussions, and new patents. Positive results from BT-600 trial and potential BioJet partnership could significantly impact Biora's future and market performance.
14 Aug
Biora Therapeutics reported a net income of US$6.47m and EPS of US$0.18 in the second quarter of 2024, a significant improvement from the previous year. The significant increase in net income and EPS is expected to have a major impact on Biora Therapeutics' future performance and market sentiment.
13 Aug
Biora Therapeutics reported successful Phase 1 trial results for BT-600 program using NaviCap platform and progress with BioJet platform. Raised additional capital of $16 million from existing investors. Discussed financial results and partnership discussions. Successful Phase 1 trial results, progress with BioJet platform, and additional capital raise are expected to significantly impact Biora Therapeutics' future trajectory and market performance.
12 Aug
Biora Therapeutics reports positive Phase 1 trial results for BT-600, secures funding, and progresses with BioJet partnership. Financial results for Q2 2024 also released. Positive Phase 1 trial results, funding, and partnership progress are expected to significantly impact Biora Therapeutics' future trajectory and market performance.
Biora Therapeutics secures $16 million funding agreement with existing investors to bridge to anticipated pharma partnership. The funding agreement is expected to support important milestones, including partnering with large pharma, potentially altering the company's trajectory.
8 Aug
Biora Therapeutics, Inc. to report Q2 2024 financial results and corporate update on August 12, 2024. The announcement of financial results and corporate update can significantly impact the company's future performance and investor sentiment.
6 Aug
Biora Therapeutics to participate in Canaccord Genuity 44th Annual Growth Conference on August 13-15, 2024. Participation in a growth conference may moderately influence key areas such as financial performance and competitive positioning.
18 Jul
Biora Therapeutics presented supplemental data from Phase 1 trial of BT-600, showing promising results in drug delivery to colon for UC treatment. The results of the Phase 1 trial demonstrate significant potential for BT-600 in improving treatment outcomes for ulcerative colitis patients.
8 Jul
Biora Therapeutics to host virtual event discussing Phase 1 trial results of BT-600 for ulcerative colitis treatment. Phase 1 trial results of BT-600 could significantly impact Biora Therapeutics' future and market performance.
Biora Therapeutics, Inc. (NASDAQ:BIOR) reported positive topline results from its BT-600 trial, confirming favorable findings in the interim update provided in April. The trial showed systemic absorption of tofacitinib at six hours, supporting the advance of BT-600 into a Phase Ib clinical trial in patients with ulcerative colitis. The positive topline results from the BT-600 trial are expected to have a significant impact on Biora Therapeutics' future and market performance, potentially altering the company's trajectory and investor sentiment.
1 Jul
Biora Therapeutics announces positive clinical trial results for BT-600, a potential treatment for ulcerative colitis, using their NaviCap platform to deliver tofacitinib directly to colonic tissue. The positive trial results for BT-600 demonstrate the potential for significant impact on Biora Therapeutics' future by advancing their targeted drug delivery platform and improving treatment outcomes for patients with GI diseases.
11 Jun
Biora Therapeutics to present preclinical data on BioJet Systemic Oral Delivery Platform at Next Gen Peptide Formulation & Delivery Summit 2024. The presentation of preclinical data on a novel drug delivery platform at a prestigious summit can significantly impact Biora Therapeutics' future development and market performance.
20 May
Biora Therapeutics presented clinical data on the NaviCap platform's device function at Digestive Disease Week 2024. The presentation of successful clinical studies demonstrating the NaviCap platform's ability to deliver therapeutics directly to the colon could significantly impact Biora Therapeutics' future and market performance.
16 May
Biora Therapeutics reported first quarter results, interim data from BT-600 trial, new patent issue, and BioJet collaboration updates. Significant impact expected on future performance due to positive trial results, new collaborations, and patent issuance.
Biora Therapeutics Inc (BIOR) Q1 2024 earnings call highlights progress in clinical development and financial challenges. The article discusses advancements in drug delivery platforms and potential partnerships, but also highlights financial challenges and risks.
15 May
Biora Therapeutics completes dosing in clinical trial for BT-600, anticipates results in late Q2 2024. Progressing well with BioJet oral delivery platform partnering process. Presented corporate update and financial results for Q1 2024. Significant impact expected on future performance with completion of clinical trial and progress in partnering process.